NeuroSense Therapeutics Ltd. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
NeuroSense Therapeutics Ltd. (NRSN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.01 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-31
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $3.01M 20-F · filed 2026-03-31 |
| 2024-12-31 | $2.30M 20-F · filed 2026-03-31 |
| 2023-12-31 | $1.81M 20-F · filed 2026-03-31 |
| 2022-12-31 | $1.41M 20-F · filed 2025-04-07 |